{"nctId":"NCT00887978","briefTitle":"Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension","startDateStruct":{"date":"2009-06"},"conditions":["Pulmonary Hypertension"],"count":310,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"UT-15C SR","type":"EXPERIMENTAL","interventionNames":["Drug: UT-15C SR"]}],"interventions":[{"name":"UT-15C SR","otherNames":["treprostinil diolamine, treprostinil diethanolamine, UT-15C"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A subject is eligible for inclusion in this study if all of the following criteria apply:\n* Between 18 and 75 years of age, inclusive.\n* Body weight at least 40 kg (approximately 90 lbs.)\n* PAH that is either idiopathic/heritable; associated with appetite suppressant or toxin use; associated with collagen vascular disease; associated with repaired congenital shunts; associated with HIV.\n* Currently receiving an approved endothelin receptor antagonist and/or an approved phosphodiesterase-5 inhibitor for at least 90 days and on a stable dose for at least the last 30 days.\n* Baseline six-minute walk distance (6MWD) between 150-425 meters\n* Previous testing (e.g., right heart catheterization, echocardiography) consistent with the diagnosis of PAH.\n* Reliable and cooperative with protocol requirements.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"6-minute Walk Distance (6MWD)","description":"Placebo-corrected change in 6MWD from Baseline to Week 16, correlates with the current clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS).\n\nThe 6MWD was to be assessed between 3 and 6 hours after the morning dose of study drug and background therapy(ies).","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"370","spread":null},{"groupId":"OG001","value":"365","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Worsening Assessment","description":"Definition of clinical worsening included patients who met at least one of the following criteria during the 16 weeks of study:\n\n1. Death (all causes excluding accident)\n2. Transplantation\n3. Atrial septostomy\n4. Hospitalization as a result of right heart failure\n5. Greater than or equal to a 20% decrease in 6MWD from Baseline (or too ill to walk) AND addition of an inhaled prostacyclin analogue, ERA, or PDE-5i\n6. Initiation of parenteral prostacyclin therapy (i.e., epoprostenol, iloprost, or treprostinil) for the treatment of PAH","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Borg Dyspnea Score","description":"The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the six-minute walk test (6MWT). The Borg dyspnea score was assessed immediately following the 6MWT. Scores ranged from 0 (for no shortness of breath) to 10 (for the greatest shortness of breath ever experienced).","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"2.47"},{"groupId":"OG001","value":"4.0","spread":"2.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"World Health Organization (WHO) Functional Class","description":"Class I: No limitation of physical activity. Class II: Slight limitation of physical activity. Class III: Marked limitation of physical activity. Class IV: Inability to carry out any physical activity without symptoms.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Symptoms of PAH","description":"Symptoms of PAH including fatigue, dyspnea, edema, dizziness, syncope, chest pain and orthopnea were assessed by the physician at Baseline and Week 16. Severity grade values (i.e., 0, 1, 2 or 3) for each symptom were provided each subject. A severity of 0 indicated no symptoms, the maximum severity was 3, indicating severe symptoms. Mean change in symptom severity from Baseline to Week 16 is described.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.9"},{"groupId":"OG001","value":"0.0","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.9"},{"groupId":"OG001","value":"-0.2","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.0"},{"groupId":"OG001","value":"0.0","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.0"},{"groupId":"OG001","value":"0.0","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.8"},{"groupId":"OG001","value":"0.2","spread":"0.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.0"},{"groupId":"OG001","value":"0.1","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"1.0"},{"groupId":"OG001","value":"0.1","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Dyspnea Fatigue Index","description":"The dyspnea-fatigue index was assessed at Baseline and Week 16. Each of the three components of the dyspnea-fatigue index were rated on a scale 0 to 4, with 0 being the worst condition and 4 being the best condition for each component. The dyspnea-fatigue index is computed by summing the three component scores.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":"2.6"},{"groupId":"OG001","value":"6.0","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"N-terminal proBNP (NT-proBNP)","description":"Serum N-terminal pro-BNP concentration was assessed at Baseline and Week 16.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1310","spread":"1663"},{"groupId":"OG001","value":"1627","spread":"2401"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"135","spread":"913"},{"groupId":"OG001","value":"136","spread":"1242"}]}]}]},{"type":"SECONDARY","title":"Quality of Life (QoL) Assessment: Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)","description":"Change in CAMPHOR Scores from Baseline to Week 16. The CAMPHOR is a health related quality of life instrument validated for pulmonary hypertension that assesses impairment (symptoms), disability (activities) and quality of life. The questionnaire is divided into three sections; Symptoms (Scores 0-25; high scores indicate more symptoms), Activity (Score 0-30; low score indicates good functioning)and Quality of Life (0-25; high scores indicate poor QoL). The sum of these scores equates to the Total score (0-80). In the CAMPHOR scores, lower scores indicate improvements.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"9.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"10.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","spread":null},{"groupId":"OG001","value":"24.5","spread":null}]}]}]},{"type":"POST_HOC","title":"6-minute Walk Distance by PAH Etiology: Idiopathic PAH (IPAH) / Heritable PAH(HPAH)","description":"Covariate analysis of change in 6MWD by PAH etiology, specifically idiopathic or heritable PAH","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"POST_HOC","title":"6-minute Walk Distance by Background PAH Therapy: PDE-5i Only","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"POST_HOC","title":"6-minute Walk Test by Background PAH Therapy: ERA Only","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5","spread":null},{"groupId":"OG001","value":"-2.5","spread":null}]}]}]},{"type":"POST_HOC","title":"6-minute Walk Test by Background PAH Therapy: ERA + PDE-5i","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":null},{"groupId":"OG001","value":"15.5","spread":null}]}]}]},{"type":"POST_HOC","title":"6-minute Walk Distance by Time to PAH Diagnosis: 0 - 0.9 Years","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":null},{"groupId":"OG001","value":"-6.0","spread":null}]}]}]},{"type":"POST_HOC","title":"6-minute Walk Distance by Time Since PAH Diagnosis: 0.9 - 1.74 Years","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.1","spread":null},{"groupId":"OG001","value":"13.0","spread":null}]}]}]},{"type":"POST_HOC","title":"6-minute Walk Distance by Years Since PAH Diagnosis: 1.8 - 3.5 Years","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]}]},{"type":"POST_HOC","title":"6-minute Walk Distance by Time Since PAH Diagnosis: 3.6 - 26.4 Years","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":null},{"groupId":"OG001","value":"16.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":157},"commonTop":["Headache","Diarrhea","Nausea","Flushing","Pain in jaw"]}}}